New triple therapy shows promise for tough lymphoma cases
NCT ID NCT02992522
First seen Oct 31, 2025 · Last updated Jun 17, 2026 · Updated 33 times
Summary
This early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work together. About 22 adults with certain types of lymphoma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.